BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.
Urs Christen, President and CEO of NVT commented, "Biosensors is strategically positioned to accelerate the adoption of our products through its highly complementary and global direct sales force focused on interventional cardiology.